NOVOFARMA, OOO, Moscow

Economic indicators

Net profit (RAS) of NOVOFARMA, OOO dropped in 2023 by 20.83% to 703.00 thousand RUB from 888.00 thousand RUB over the same period in 2022, the company informed.

Revenue decreased in the accounting period by 11.68% to 23.61 million RUB from 26.73 million RUB in 2022; cost of goods sold decreased by 12.04% to 21.32 million RUB from 24.24 million RUB; sales profit fell by 27.76% to 890.00 thousand RUB from 1.23 million RUB.

Net profit (RAS) of NOVOFARMA, OOO grew over 2022 5.84 times to 888.00 thousand RUB from 152.00 thousand RUB over 2021, the company informed.

Revenue increased in the accounting period 1.75 times to 26.73 million RUB from 15.31 million RUB over 2021; cost of goods sold grew 1.79 times to 24.24 million RUB from 13.56 million RUB; sales profit went up 1.74 times to 1.23 million RUB from 708.00 thousand RUB.

Net profit (RAS) of NOVOFARMA, OOO dropped in 2021 3.11 times to 152.00 thousand RUB from 472.00 thousand RUB over the same period in 2020, the company informed.

Revenue decreased in the accounting period by 31.12% to 15.31 million RUB from 22.22 million RUB in 2020; cost of goods sold decreased by 33.27% to 13.56 million RUB from 20.32 million RUB; sales profit went up by 6.63% to 708.00 thousand RUB from 664.00 thousand RUB.

Net profit (RAS) of NOVOFARMA, OOO dropped in 2020 by 1.05% to 472.00 thousand RUB from 477.00 thousand RUB over the same period in 2019, the company informed.

Revenue increased in the accounting period by 23.17% to 22.22 million RUB from 18.04 million RUB over 2019; cost of goods sold grew by 21.49% to 20.32 million RUB from 16.72 million RUB; sales profit went up by 0.61% to 664.00 thousand RUB from 660.00 thousand RUB.

Companies in the region

• MIRTA
• PM-AVTO
• EKSPOTREYD
• ITS
• SKHK BOGES